Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229149 | 0.85 | ALDH1A1 (0.55) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1176355 | 0.84 | ALDH1A1 (0.54) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL23162717 | 0.82 | ADORA2A (0.53) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL29623216 | 0.82 | ADORA2A (0.53) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL6440893 | 0.79 | ADORA2A (0.68) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL6218562 | 0.77 | KMT2A (0.76) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL24747412 | 0.75 | ADORA2A (0.55) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL7149747 | 0.74 | ALDH1A1 (0.55) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2132489 | 0.74 | KMT2A (0.60) | KMT2ACYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL19716807 | 0.73 | ADORA1 (0.53) | KMT2AALDH1A1MEN1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4038065-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | disclosed |
| CN-114450277-A | Substituted pyrimidines for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021063852-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021063852-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-2260044-A2 | THIENOPYRIMIDINES | Merck Patent GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009124653-A2 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TYMP, HPRT1, DPYD | KMT2A 2822/4885CYP1A2 180/4885CYP2C9 177/4885 |
| US-20110028472-A1 | THIENOPYRIMIDINES | TGFBR1, TYMP, TGFBR2 | KMT2A 1898/4885CYP1A2 1757/4885CYP2C9 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.